WO1999014197A1 - Substituted isoquinolines as anticonvulsivants - Google Patents

Substituted isoquinolines as anticonvulsivants Download PDF

Info

Publication number
WO1999014197A1
WO1999014197A1 PCT/GB1998/002728 GB9802728W WO9914197A1 WO 1999014197 A1 WO1999014197 A1 WO 1999014197A1 GB 9802728 W GB9802728 W GB 9802728W WO 9914197 A1 WO9914197 A1 WO 9914197A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
tetrahydroisoquinolin
urea
disorders
alkyl
Prior art date
Application number
PCT/GB1998/002728
Other languages
French (fr)
Inventor
Mervyn Thompson
Roderick Alan Porter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Priority to CA002303777A priority Critical patent/CA2303777A1/en
Priority to EP98942869A priority patent/EP1005459A1/en
Priority to JP2000511748A priority patent/JP2001516745A/en
Publication of WO1999014197A1 publication Critical patent/WO1999014197A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.
  • WO96/39382 discloses the preparation of N-heterocycyl-ureas as 5-HT antagonists, including the compound N-(l -methyl- lH-indol-5-yl)-N'-( 1,2, 3,4-tetrahydro-7- isoquinolinyl)-urea.
  • urea compounds of formula (I) below possess anti- convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
  • Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
  • MS multiple sclerosis
  • ALS amyotrophic lateral sclerosis
  • the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:
  • R is hydrogen, phenylC ⁇ _6 alkyl or C1.5 alkyl
  • R is hydrogen or up to three substituents independently selected from halogen, NO 2 , CN, N 3 , C ⁇ _ 6 alkylO-, C ⁇ _ 6 alkylS-, C ⁇ _ 6 alkyl, Cj ⁇ haloalkyl, C3_5cycloalkyl, C3_gcycloalkyl-C 4alkyl-, C j .galkenyl, C ⁇ .galkynyl, C ⁇ _6haloalkylCO-, C ⁇ _ 6 alkylCO-, C 3.6 cycloalkylCO-, C3_ cycloalkyl-C ⁇ 4alkylCO-.
  • the compounds of this invention are typically N-(tetrahydroisoquinolinyl)-N' -optionally substituted phenyl-ureas/thioureas.
  • the compounds of the invention may be
  • the phenyl moiety may be substituted by up to three, preferably 2 or 1, groups.
  • alkyl groups including alkyl groups that are part of another moiety, may be straight chain or branched.
  • Alkyl groups are typically C g alkyl, especially C 4 alkyl, such as methyl, ethyl, «-propyl, wo-propyl, n-butyl, t-butyl.
  • Aromatic rings such as the aromatic ring in the bicyclic heterocyclic moiety in formula (I)
  • R may optionally be substituted with one or more independently selected substituents such as halogen or C ⁇ _g alkyl, C g alkoxy or C ⁇ _ alkylcarbonyl groups, or other optional subtituents indicated below.
  • Suitable C 3 _g cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • Suitable halo substituents include fluoro, chloro, iodo and bromo, which may also appear in haloalkyl, haloalkyloxy and haloalkyl carbonyl groups mentioned above, examples of which are trifluoromethyl, trifluoromethoxy and trifluoroacetyl.
  • R " represents heterocyclyl
  • this group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated. for example containing 1 , 2 or 3 heteroatoms selected from oxygen, nitrogen or sulphur, for example oxazolyl, thienyl or piperidinyl.
  • the heterocyclyl group may contain up to 5, more preferably 1, 2 or 3 optional substituents.
  • a substituent for a heterocyclyl group is selected from halogen, (C ⁇ _5)alkyl, aryl(C ⁇ _6)alkyl, (C ⁇ _6)alkoxy, (C ⁇ _6)alkoxy(C ⁇ _6)alkyl, halo(C 6)alkyl, hydroxy, amino, mono- and di-N-(C ⁇ _6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C 6)alkylcarbonyl, aryloxycarbonyl, (C ⁇ .
  • an adjacent pair of R ⁇ together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring, it is preferably a 5- to 7-membered ring, which may be aromatic or non-aromatic.
  • Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example, pyrrole or pyrrolidine.
  • a carbocyclic or heterocyclic ring formed by an adjacent pair of R ⁇ together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one or more substituents, e.g. up to 3 substituents.
  • substituents for the carbocyclic or heterocyclic ring include; halogen, (C ⁇ _6)alkyl, aryl(C 6)alkyl, (C ⁇ _ 6)alkoxy, (C ⁇ _6)alkoxy(C ⁇ _6)alkyl, halo(C ⁇ _g)alkyl, hydroxy, amino, mono- and di-N- (C ⁇ _6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C ⁇ _g)alkylcarbonyl, aryloxycarbonyl, (C ⁇ _6)alkoxycarbonyl(C 6)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (C ⁇ _6)alkylthio, (C ⁇ _6)alkylsulphinyl, (C ⁇ _6)alkylsulf
  • R as hydrogen, benzyl, methyl, ethyl, wo-propyl or t-butyl
  • R2 as hydrogen, methyl, ethyl, n-butyl, wo-propyl, t-butyl, phenyl, benzyl, methoxy, ethoxy, n-propoxy, /.r ⁇ -propoxy, n-butoxy, phenoxy, benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl, pivaloyl, wo-butyroyl, benzoyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, carbomethoxy, carboethoxy, methylthio, n-propylsulfonyl, isopropylsulfonyl, dimethylsulfamoyl or oxazolyl, R° and R ⁇ are hydrogen, acetyl or methanesulfonyl, or two R groups linked to form naphthyl, indolyl
  • R! is hydrogen or methyl
  • R ⁇ is hydrogen, methyl, ethyl, t-butyl, methoxy, ethoxy, w ⁇ -propoxy, phenoxy, benzyloxy, methylthio, bromo, chloro, fluoro, nitro, cyano, acetyl, benzoyl, trifluoromethyl, trifluoromethoxy, carbomethoxy, carboethoxy, amino, acetylamino, methanesulphonylamino or oxazolyl, or two R2 groups form methylindolyl or acetylindolinyl or naphthyl.
  • these compounds When synthesised, these compounds may be in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in preparing pharmaceutically acceptable salts.
  • the compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.
  • the compounds of this invention possess anti-convulsant activity and are therefore believed to be useful for adminstration to mammals in the treatment and/or prevention of the disorders mentioned above, especially for humans, but also as a veterinary treatment.
  • the administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration.
  • An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal.
  • a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound.
  • Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.
  • the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.
  • compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories.
  • Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
  • Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
  • the tablets may be coated according to well known methods in the art.
  • Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
  • Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
  • Suitable lubricants include, for example, magnesium stearate.
  • Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
  • solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate,
  • Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
  • fluid unit dose forms are prepared containing the compound and a sterile vehicle.
  • the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
  • Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
  • adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
  • compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
  • the present invention provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with ADDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
  • epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive
  • Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • MS multiple sclerosis
  • ALS amyotrophic lateral sclerosis
  • the present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post- traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
  • Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • MS multiple sclerosis
  • ALS amyotrophic lateral sclerosis
  • the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
  • epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other
  • Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
  • MS multiple sclerosis
  • ALS amyotrophic lateral sclerosis
  • the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g.
  • Giles de la Tourette's syndrome traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
  • MS multiple sclerosis
  • ALS amyotrophic lateral sclerosis
  • Another aspect of the invention provides a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (H)
  • R 1 A is R* as defined for formula (I) or a group convertible to R 1
  • P is NH2 or NCX, X being as defmed for formula (I), with a compound of formula (III)
  • R ⁇ A is R ⁇ as defined for formula (I) or a group or groups convertible to R ⁇ , and where required converting a R ⁇ or R- ⁇ A group to a R' or R ⁇ group, converting one R! or R2 group to another R* or R ⁇ group, converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.
  • Conversions of an R ⁇ or R ⁇ A group to a R or R ⁇ group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below.
  • Interconversion of one R* or R ⁇ group to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.
  • the compound of formula (H) which can be reduced, for example using sodium borohydride, to the compound of formula (H).
  • the compound of formula (V) can be hydrogenated, for example using hydrogen at 50psi in a solution of acetic/sulphuric acid with a platinum oxide catalyst.
  • a compound of formula (H) in which P is NH2 may be prepared directly from the corresponding nitro compound by catalytic hydrogenation. More specifically 7-amino- tetrahydroisoquinolines may be prepared by the procedure of G E Stokker, Tet. Lett. 1996, 37, 5453.
  • the compound of formula (LI) can be obtained by direct hydrogenation of the compounds of formula (IV) or (VI), using the reagents already described.
  • the NH may be protected conventionally, for example by making R t-butoxycarbonyl, prior to formation of the urea, and then deprotected under standard conditions, for example using trifluoroacetic acid/methylene chloride.
  • Compounds of formula (IH) in which Q is iso(thio)cyanate are commercially available or may be prepared by formation of iso(thio)cyanates from commercially available substituted phenyl compounds using conventional procedures such as described by I T Forbes et al , J.Med.Chem., 1993, 36, 1104, and in Fieser and Fieser, Reagents for Organic Synthesis Vol I.
  • an isocyanate may be prepared by stirring a relevant amine with one equivalent of carboxyl diimidazole in a suitable solvent such as dichloromethane at room temperature, and then evaporated to dryness in vacuo.
  • Isothiocyanates may be prepared by reaction of the relevant amine with carbon disulphide in pyridine in the presence of dicyclohexylcarbodiimide.
  • Compounds of formula (LT) in which P is iso(thio)cyanate may be similarly prepared starting from the amines of formula (LT) described above.
  • Compounds of formula (HI) in which Q is amino are commercially available or may be prepared by formation of amines on commercially available substituted phenyl compounds using conventional procedures.
  • the compounds of the present invention may contain a chiral centre, and therefore the above processes may produce a mixture of diastereoisomers.
  • a single diastereoisomer may be prepared by separating such a mixture of diastereoisomers which has been synthesised using a racemic starting material, or by synthesis using an optically pure starting material.
  • the compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated.
  • solvent of crystallisation may be present in the crystalline product.
  • some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. Crystallisation procedures will usually produce stoichiometric hydrates. Compounds containing variable amounts of water may be produced by processes such as lyophilisation.
  • the compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitable at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight.
  • An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.
  • the present invention also includes pharmaceutically acceptable salts and derivatives of the compounds of the invention.
  • Salt formation may be possible when one of the substituents carries an acidic or basic group.
  • Salts may be prepared by salt exchange in conventional manner.
  • Acid-addition salts may be pharmaceutically acceptable or non-pharmaceutically acceptable. In the latter case, such salts may be useful for isolation and purification of the compound of the invention, or intermediates thereto, and will subsequently be converted into a pharmaceutically acceptable salt or the free base.
  • the amine D3 (2.08g; 11.7 mmol) was treated with 88% formic acid (3.45ml) and 37% aqueous formaldehyde (5.88ml) at 80°C for 2h according to the procedure of G.M. Carrera and D.S. Garvey, J. Het. Chem., 1992, 29, 847. Basification with 10% sodium hydroxide followed by work-up with ethyl acetate afforded an orange gum (2.3g). Chromatography on Kiesegel 60 in 0-3% methanol - ethyl acetate gave the title compound as an orange solid (1.7g).
  • the title compound was prepared from the compound of Description D3 using di t-butyl dicarbonate in 10% aqueous hydroxide in dioxan at 25°C followed by catalytic hydrogenation according to the procedure described for D5.
  • urea (a) (540mg; 1.32 mmol) in 10% aqueous methanol(80ml) and potassium carbonate (lg) was stirred at room temperature overnight. The mixture was partitioned between chloroform and water and the organic phase dried over magnesium sulfate. Evaporation in vacuo gave a pale yellow solid which was recrystallised from chloroforrmhexane (300mg, 72%). m.p. 232-5 °C.
  • N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-cyano-3-methylphenyl) urea The isocyanate D10 (160mg) was dissolved in dimethylformamide (10ml), 6-methyl-2- aminobenzonitrile (0.13g) added and the mixture heated at 100°C for 3h. Dimethylformamide was removed at reduced pressure and the residue partitioned between dichloromethane and water. The organic phase was washed with water, dried MgSO4) and solvent removed at reduced pressure.
  • the title compound was prepared in 42% yield from 3-isopropoxyaniline and the isocyanate D10 using the method of Example 43.
  • the title compound was prepared in 72% yield from 3-(l,3-oxazol-5-yl)aniline and the isocyanate D10 using the method of Example 43.
  • the title compound was prepared in 24% yield from amine D9 and 3, 5-dinitroaniline using a method similar to that of Example 69.
  • the title compound was prepared in 20% yield from amine D9 and 3-bromo-4- methoxyaniline using a method similar to that of Example 69.
  • N- ⁇ 3-[3-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl ⁇ acetamide hydrochloride A solution of N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-aminophenyl) urea E74 (0.296g) and triethylamine (0.151g) in dichloromethane was treated with acetyl chloride (0.078g) and stirred for 6h. Aqueous sodium hydrogen carbonate was added with vigorous stirring and the precipitated solid collected by filtration. The material was dissolved in methanol and treated with an excess of ethereal HC1. The precipitated title compond (0.145g) was collected by filtration and dried in vacuo.
  • WO 92/22293 discloses compounds having anti-convulsant activity, including ter alia the compound tr ⁇ nO+)-6-acetyl-4S-(4-fluorobenzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-l-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham). The affinity of test compounds to the novel receptor site is assessed as follows.
  • Whole forebrain tissue is obtained from rats.
  • the tissue is first homogenised in buffer (usually 50mM Tris/HCl, pH 7.4).
  • the homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.
  • the affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested.
  • the decrease in the level of specific [3H]- Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.
  • the maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties 1.
  • anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.
  • mice (naive male, Charles River, U.K. CD-I strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC50) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)2. Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)3.
  • the CC50 In control animals the CC50 is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.
  • the percentage increase or decrease in CC50 for each group compared to the control is calculated. Studies are carried out using a Hugo Sachs Electronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.
  • Drugs are suspended in 1 % methyl cellulose.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

N-(tetrahydroisoquinolinyl)-N'-phenyl-ureas/thioureas of general formula (I) are useful for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).

Description

SUBSTITUTED ISOQUINOLINES AS ANTICONVULSIVANTS
This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.
WO96/39382 (Fujisawa) discloses the preparation of N-heterocycyl-ureas as 5-HT antagonists, including the compound N-(l -methyl- lH-indol-5-yl)-N'-( 1,2, 3,4-tetrahydro-7- isoquinolinyl)-urea.
It has now been surprisingly found that urea compounds of formula (I) below possess anti- convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
Accordingly, the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000003_0001
(I)
where X is O or S R is hydrogen, phenylC^_6 alkyl or C1.5 alkyl, R is hydrogen or up to three substituents independently selected from halogen, NO2, CN, N3, Cι _6 alkylO-, Cχ_6 alkylS-, C ι _6 alkyl, Cj^haloalkyl, C3_5cycloalkyl, C3_gcycloalkyl-C 4alkyl-, Cj.galkenyl, C^.galkynyl, Cι_6haloalkylCO-, Cι _6alkylCO-, C3.6cycloalkylCO-, C3_ cycloalkyl-Cμ4alkylCO-. phenyl, phenoxy, benzyloxy, benzoyl, phenyl-Cι _4alkyl-, O-Cι.6haloalkyl, CO2Ci_4alkyl, S(O)2Cι_6alkyl, Cι_4alkylsulfamoyl or heterocyclyl, or -NR R where R" is hydrogen, C1.4 alkyl or S(O)2Cι_6alkyl, and R7 is hydrogen, Cι _4alkyl, -CHO, S(O)2Cι_6alkyl -CO2C1.4alkyl or -COC^alkyl, or an adjacent pair of R^ groups together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.
The compounds of this invention are typically N-(tetrahydroisoquinolinyl)-N' -optionally substituted phenyl-ureas/thioureas. The compounds of the invention may be
(tetrahydroisoquinolin-5-yl), (tetrahydroisoquinolin-6-yl), (tetrahydroisoquinolin-7-yl) or (tetrahydroisoquinolin-8-yl) ureas/thioureas, especially (tetrahydroisoquinolin-5-yl) and (tetrahydroisoquinolin-7-yl) ureas/thioureas .
The phenyl moiety may be substituted by up to three, preferably 2 or 1, groups.
In the formula (I), alkyl groups, including alkyl groups that are part of another moiety, may be straight chain or branched. Alkyl groups are typically C g alkyl, especially C 4 alkyl, such as methyl, ethyl, «-propyl, wo-propyl, n-butyl, t-butyl.
Aromatic rings, such as the aromatic ring in the bicyclic heterocyclic moiety in formula (I)
9 and phenyl groups, including phenyl groups that are part of other moieties, in R may optionally be substituted with one or more independently selected substituents such as halogen or C^ _g alkyl, C g alkoxy or C γ_ alkylcarbonyl groups, or other optional subtituents indicated below.
Suitable C3_g cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
Suitable halo substituents include fluoro, chloro, iodo and bromo, which may also appear in haloalkyl, haloalkyloxy and haloalkyl carbonyl groups mentioned above, examples of which are trifluoromethyl, trifluoromethoxy and trifluoroacetyl. When any R" represents heterocyclyl, this group is preferably a 5- to 10-membered monocyclic or bicyclic ring, which may be saturated or unsaturated. for example containing 1 , 2 or 3 heteroatoms selected from oxygen, nitrogen or sulphur, for example oxazolyl, thienyl or piperidinyl. The heterocyclyl group may contain up to 5, more preferably 1, 2 or 3 optional substituents.
Preferably a substituent for a heterocyclyl group is selected from halogen, (Cι _5)alkyl, aryl(Cι_6)alkyl, (C ι _6)alkoxy, (Cι_6)alkoxy(C ι_6)alkyl, halo(C 6)alkyl, hydroxy, amino, mono- and di-N-(Cι_6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(C 6)alkylcarbonyl, aryloxycarbonyl, (C\. 6)alkoxycarbonyl(C ι_6)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (Cι_6)alkylthio, (Cι_6)alkylsulphinyl, (Cι_6)alkylsulphonyl, heterocyclyl and heterocyclyl(C ι _6)alkyl.
When an adjacent pair of R^ together with the carbon atoms to which they are attached form a carbocyclic or heterocyclic ring, it is preferably a 5- to 7-membered ring, which may be aromatic or non-aromatic. Heterocyclic rings preferably contain 1, 2 or 3 heteroatoms selected from oxygen, nitrogen and sulphur; for example, pyrrole or pyrrolidine. A carbocyclic or heterocyclic ring formed by an adjacent pair of R^ together with the carbon atoms to which they are attached may be optionally substituted on carbon or nitrogen by one or more substituents, e.g. up to 3 substituents. Examples of suitable substituents for the carbocyclic or heterocyclic ring include; halogen, (Cι _6)alkyl, aryl(C 6)alkyl, (Cι_ 6)alkoxy, (Cι_6)alkoxy(Cι_6)alkyl, halo(C ι_g)alkyl, hydroxy, amino, mono- and di-N- (Cι_6)alkyl-amino, acylamino, carboxy, carboxy salts, carboxy esters, carbamoyl, mono- and di-N-(Cι_g)alkylcarbonyl, aryloxycarbonyl, (Cι _6)alkoxycarbonyl(C 6)alkyl, aryl, oxy groups, ureido, guanidino, sulphonylamino, aminosulphonyl, (Cι_6)alkylthio, (Cι_6)alkylsulphinyl, (Cι_6)alkylsulphonyl, heterocyclyl and heterocyclyl(Cι_6)alkyl.
A suitable group of compounds of formula (I) have
R as hydrogen, benzyl, methyl, ethyl, wo-propyl or t-butyl
R2 as hydrogen, methyl, ethyl, n-butyl, wo-propyl, t-butyl, phenyl, benzyl, methoxy, ethoxy, n-propoxy, /.rø-propoxy, n-butoxy, phenoxy, benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl, pivaloyl, wo-butyroyl, benzoyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, carbomethoxy, carboethoxy, methylthio, n-propylsulfonyl, isopropylsulfonyl, dimethylsulfamoyl or oxazolyl, R° and R^are hydrogen, acetyl or methanesulfonyl, or two R groups linked to form naphthyl, indolyl or indolinyl, optionally substituted by acetyl or methyl.
In a particular group of compounds of formula (I), R! is hydrogen or methyl,
R^ is hydrogen, methyl, ethyl, t-butyl, methoxy, ethoxy, wø-propoxy, phenoxy, benzyloxy, methylthio, bromo, chloro, fluoro, nitro, cyano, acetyl, benzoyl, trifluoromethyl, trifluoromethoxy, carbomethoxy, carboethoxy, amino, acetylamino, methanesulphonylamino or oxazolyl, or two R2 groups form methylindolyl or acetylindolinyl or naphthyl.
Examples of compounds of formula (I) are:
N-(l,2,3,4-te :rahydroisoquinolin-7-yl)-N'-(3-nitrophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (3-nitrophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (4-ethoxyphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N'- (4-ethoxyphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (3-trifluoromethylphenyl)thiourea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N' (3-trifluoromethylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N' (3 -methoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N' (3-bromophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N' (4-trifluoromethylphenyl)urea N-(2-methyl- ,2,3 ,4-tetrahydroisoquinolin-7-yl)-N '■ (5-chloro-2,4-dimethoxyphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N' (4-tert-butyl, 2-methoxyphenyl)urea N-(2-methyl- ,2,3 ,4-tetrahydroisoquinolin-7-yl)-N - (phenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (3-acetylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (2-methylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (2-methoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-chlorophenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N - (3-chloro-6-methoxyphenyl)urea N-(2-methyl- ,2,3 ,4-tetrahydroisoquinolin-7-yl)-N '■ (3,5-di-trifluoromethylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (4-trifluoromethoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahdyroisoquinolin-7-yl)-N'- (3-chloro-4-methylphenyl)urea N-(2-methyl- ,2,3,4,-tetrahydroisoquinolin-5-yl)-N -(3-trifluoromethylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N - (5-chloro-2,4-dimethoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N' (3-nitrophenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N' (3-bromophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N' (3-methoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-trifluoromethyoxyphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-trifluoromethylphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(phenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoqinolin-5-yl)-N'-(3-acetylphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-chloro-4-methylphenyl)urea
N-(2-methy ,2,3,4~tetrahydroisoquinolin-5-yl)-N'-(3-chloro-6-methoxyphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-chlorophenyl)urea
N-(2-methy ,2,3,4,-tetrahydroisoquinolin-5-yl)-N'-(2-methoxyphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2-methylphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3,5-di-trifluoromethylphenyl)urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-5-yl-N'-(3-trifluoromethylphenyl)thiourea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-carbomethoxyphenyl) urea
N-(2-methy ,2,3 ,4-tetrahydroisoquinolin-7-yl)-N '-(2, 3-dimethylphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N -(2-methoxy-3-chlorophenyl) urea
N-(2-methy ,2,3, 4-tetrahydroisoquinolin-7-yl)-N'-(l -naphthyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-methyl-3-nitrophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-cyanophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-cyano-3-methylphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N -(l-acetylindolin-7-yl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-cyanophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-ethylphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3, 5-dinitrophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2, 3-dichlorophenyl) urea
N-(2-methy: ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-chloro-4-fluorophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-chloro-5-trifluoromethylphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-isopropoxyphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-ethoxyphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-tertbutylphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N [3-(l,3-oxazol-5-yl)phenyl] urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-benzyloxyphenyl) urea
N-(2-methy] ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-phenoxyphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-fluorophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (2-fluorophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-methylthiophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-carboethoxyphenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (4-fluorophenyl) urea
N-(2-methy ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3, 4-difluorophenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-benzoylphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-methoxyphenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-7-yl)-N -(3-bromo-4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-bromo-4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2,3-dichlorophenyl) urea
N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2-chloro-5-trifluoromethylphenyl) urea
N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-chloro-4-fluorophenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N -(3-ethylphenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N -(3, 5-dinitrophenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-cyanophenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N '-(3-bromo-4-methoxyphenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-7-yl)-N '-(3-aminophenyl) urea N-{3-[3-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl}acetamide N- { 3-[3-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl } bis methanesulphonimide N-(2-methyl- 1 ,2,3 ,4-tetrahydroisoquinolin-5-yl)-N '-( 1 -methylindol-5-yl) urea.
When synthesised, these compounds may be in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in preparing pharmaceutically acceptable salts. The compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.
The above-listed compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, form a preferred aspect of the present invention.
Where compounds of the present invention possess chiral centres and as such may exist in different enantiomeric forms, the present invention extends to each enantiomeric form and mixtures thereof including diastereoisomers and racemates.
The compounds of this invention possess anti-convulsant activity and are therefore believed to be useful for adminstration to mammals in the treatment and/or prevention of the disorders mentioned above, especially for humans, but also as a veterinary treatment. The administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal, topical or transdermal administration. An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50, 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.
It is greatly preferred that the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.
Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable and infusable solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be coated according to well known methods in the art.
Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
These solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.
For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.
Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.
As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
Accordingly, in a further aspect, the present invention provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with ADDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
The present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post- traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis (ALS).
Another aspect of the invention provides a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (H)
(LI)
where R1 A is R* as defined for formula (I) or a group convertible to R1, and P is NH2 or NCX, X being as defmed for formula (I), with a compound of formula (III)
(HI)
where Q is NCX or NH2 and different from P, X being as defined for formula (I), and R^A is R^ as defined for formula (I) or a group or groups convertible to R^, and where required converting a R^ or R-^A group to a R' or R^ group, converting one R! or R2 group to another R* or R^ group, converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.
Conventional conditions for condensation of isocyanates or isothiocyanates with amines may be used, for example treatment in an inert solvent such as toluene, DMF or dichloromethane at ambient or elevated temperature.
Conversions of an R^ or R^A group to a R or R^ group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below. Interconversion of one R* or R^ group to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a more complex or reactive substituent at the end of a synthetic sequence.
Compounds of formula (LI) in which P is NH2 may be prepared from the corresponding unsaturated compound of formula (IV)
(IV)
by reaction with a compound R1 AZ where Z is a leaving group such as halogen, especially iodo, or tosylate to obtain an intermediate of formula (V)
(V)
which can be reduced, for example using sodium borohydride, to the compound of formula (H). Alternatively the compound of formula (V) can be hydrogenated, for example using hydrogen at 50psi in a solution of acetic/sulphuric acid with a platinum oxide catalyst.
Another route is from a precursor of formula (VI)
(VI) which can be reacted with R Z, preferably as a tosylate, to obtain the intermediate of formula (VII)
(VH)
which can then be hydrogenated under the conditions previously described to prepare the compound of formula (LI).
Compounds of formulae (IV) and (VI) and the reagents used are commercially available, or can be prepared from commercially available materials using conventional procedures described in the literature.
Alternatively, a compound of formula (H) in which P is NH2 may be prepared directly from the corresponding nitro compound by catalytic hydrogenation. More specifically 7-amino- tetrahydroisoquinolines may be prepared by the procedure of G E Stokker, Tet. Lett. 1996, 37, 5453.
When R is hydrogen, the compound of formula (LI) can be obtained by direct hydrogenation of the compounds of formula (IV) or (VI), using the reagents already described. The NH may be protected conventionally, for example by making R t-butoxycarbonyl, prior to formation of the urea, and then deprotected under standard conditions, for example using trifluoroacetic acid/methylene chloride.
Compounds of formula (IH) in which Q is iso(thio)cyanate are commercially available or may be prepared by formation of iso(thio)cyanates from commercially available substituted phenyl compounds using conventional procedures such as described by I T Forbes et al , J.Med.Chem., 1993, 36, 1104, and in Fieser and Fieser, Reagents for Organic Synthesis Vol I. For example an isocyanate may be prepared by stirring a relevant amine with one equivalent of carboxyl diimidazole in a suitable solvent such as dichloromethane at room temperature, and then evaporated to dryness in vacuo. Isothiocyanates may be prepared by reaction of the relevant amine with carbon disulphide in pyridine in the presence of dicyclohexylcarbodiimide.
Compounds of formula (LT) in which P is iso(thio)cyanate may be similarly prepared starting from the amines of formula (LT) described above. Compounds of formula (HI) in which Q is amino are commercially available or may be prepared by formation of amines on commercially available substituted phenyl compounds using conventional procedures.
Where intermediates disclosed for the above processes are novel compounds, they also form part of this invention.
The compounds of the present invention may contain a chiral centre, and therefore the above processes may produce a mixture of diastereoisomers. A single diastereoisomer may be prepared by separating such a mixture of diastereoisomers which has been synthesised using a racemic starting material, or by synthesis using an optically pure starting material.
The compounds of this invention may be in crystalline or non-crystalline form, and, if crystalline, may optionally be hydrated or solvated. When some of the compounds of this invention are allowed to crystallise or are recrystallised from organic solvents, solvent of crystallisation may be present in the crystalline product. Similarly, some of the compounds of this invention may be crystallised or recrystallised from solvents containing water. In such cases water of hydration may be present in the crystalline product. Crystallisation procedures will usually produce stoichiometric hydrates. Compounds containing variable amounts of water may be produced by processes such as lyophilisation.
The compounds according to the invention are suitably provided in substantially pure form, for example at least 50% pure, suitable at least 60% pure, advantageously at least 75% pure, preferably at least 85% pure, more preferably at least 95% pure, especially at least 98% pure, all percentages being calculated as weight/weight. An impure or less pure form of a compound according to the invention may, for example, be used in the preparation of a more pure form of the same compound or of a related compound (for example a corresponding derivative) suitable for pharmaceutical use.
The present invention also includes pharmaceutically acceptable salts and derivatives of the compounds of the invention. Salt formation may be possible when one of the substituents carries an acidic or basic group. Salts may be prepared by salt exchange in conventional manner. Acid-addition salts may be pharmaceutically acceptable or non-pharmaceutically acceptable. In the latter case, such salts may be useful for isolation and purification of the compound of the invention, or intermediates thereto, and will subsequently be converted into a pharmaceutically acceptable salt or the free base.
The preparation of compounds of formula (LI) is illustrated by the following Descriptions; the preparation of compounds of this invention is illustrated by the following Examples. The utility of compounds of this invention is shown by the Pharmacological Data that follow the Examples.
Description 1
N-2-(4-Nitrophenyl)ethyl-trifluoroacetamide
A solution of trifluoroacetic anhydride (10.6ml) in dichloromethane (100ml) was added dropwise to a stirred solution of 2,6-lutidine (17.44ml) and 4-nitrophenethylamine hydrochloride (15.2g; 75 mmol) at 0°C. The mixture was stirred at 25°C overnight under argon and then washed with dilute citric acid (x2), brine and dried over Na2SO4. The material in the organic phase gave the title compound as a pale yellow solid (19.04g).
Description 2
7-Nitro-l,2,3,4-tetrahydro-2-trifluoroacetyl-isoquinoline
The nitro compound DI (2.26g; 9.15 mmol) and paraformaldehyde (0.45g; 14.4 mmol) in acetic acid (10ml) and cone. H2SO4 (15ml) were stirred at 25°C for 20h according to the procedure of G.E. Stokker., Tet. Lett., 1996, 37, 5453. Work up afforded the title compound as a white solid (2.17g).
lH NMR (CDCI3) δ: 3.10 (2H, m), 3.92 (2H, m), 4.85 + 4.92 (2H, 2xs), 7.38 (IH, t), 8.10 (2H, m); /z (El): 274 (M+)
Description 3
7-Nitro-l,2,3,4-tetrahydroisoquinoline The trifluoroacetamide D2 (17.22g; 63 mmol) was hydrolysed at room temperature using a solution of potassium carbonate (46.6g) in 10% aqueous methanol (660ml). Work-up with dichloromethane gave the title compound (1 lg).
Description 4
2-MethyI-7-nitro-l,2,3,4-tetrahydroisoquinoline
The amine D3 (2.08g; 11.7 mmol) was treated with 88% formic acid (3.45ml) and 37% aqueous formaldehyde (5.88ml) at 80°C for 2h according to the procedure of G.M. Carrera and D.S. Garvey, J. Het. Chem., 1992, 29, 847. Basification with 10% sodium hydroxide followed by work-up with ethyl acetate afforded an orange gum (2.3g). Chromatography on Kiesegel 60 in 0-3% methanol - ethyl acetate gave the title compound as an orange solid (1.7g).
m/z (CI): 193 (MH+).
Description 5
7-Amino-2-methyl-l,2,3,4-tetrahydroisoquinoline
The 7-nitro compound D4 (0.25g; 1.3 mmol) in methanol (40ml) was hydrogenated over 10% palladium on carbon (lOOmg) at atmospheric pressure overnight. The catalyst was removed by filtration through a pad of Kieselguhr and evaporation in vacuo gave the title compound as a white solid (213mg).
m/z (CI): 163 (MH+)
Description 6
7-Amino-2-(t-butyloxycarbonyl)-l,2,3,4-tetrahydroisoquinoline
The title compound was prepared from the compound of Description D3 using di t-butyl dicarbonate in 10% aqueous hydroxide in dioxan at 25°C followed by catalytic hydrogenation according to the procedure described for D5.
Description 7 7-Amino-l,2,3,4-tetrahydro-2-trifluoroacetyl-isoquinoline
The 7-nitro compound D2 (0.99g; 3.6 mmol) in ethanol (50ml) was hydrogenated over 10% palladium on carbon (450mg) at atmospheric pressure for 4h. The catalyst was removed by filtration through a pad of Celite and evaporation in vacuo gave the title compound as a white solid (840mg).
! H NMR (250MHz, CDC13) δ: 2.84 (2H, t), 3.23 (2H, b. s.), 3.82 (2H, m), 4.66 (2H,d, restricted rotation around C-l), 6.47 (IH, m), 6.57 (lH,m ), 6.96 (IH, m)
Description 8
5 - Amino-2-methy lisoquinolinium iodide
To a solution of 5-aminoisoquinoline (14.4g, lOOmmol) in acetone (300ml) was added iodomethane (14.4ml). The solution was briefly stirred and then allowed to stand for 2h.
The yellow precipitate was then filtered, washed with acetone and dried to afford the title compound as a yellow solid (18.8g).
Description 9
5-Amino-2-methyl-l,2,3,4-tetrahydroisoquinoline
Sodium borohydride (17.8g, 0.47mol) was added portionwise over 2h to an ice cold solution of 5-amino-2-methylisoquinolinium iodide D8 (18.8g, 65mmol) in methanol (1.5L) and water (60ml). The mixture was then stirred at 25°C for 18h. and concentrated in vacuo. The residue was extracted into water and dichloromethane. The organic layer was dried (Na2SO4) and concentration in vacuo gave the title compound (8.87g).
Description 10
2-Methyl-l,2,3,4-tetrahydroisoquinoline-7-isocyanate
The amine D5 (0.25g) and carbonyl di-imidazole (0.24g) in dichloromethane were stirred at 25°C for lh. Solvent was removed at reduced pressure below 40°C. Example 1
(a) N-(l,2,3,4-Tetrahydro-2-trifluoroacetyl-isoquinolin-7-yl)-N '-(3-nitrophenyl) urea
A solution of amine D7 (400mg; 1.64 mmol) in dichloromethane (5ml) was treated with a solution of 3-nitrophenylisocyanate (295mg; 1.80 mmol) in toluene (10ml) and the mixture kept at room temperature under argon. After 20h., the resultant cream precipitate was removed by filtration and washed well with ether/hexane and dried in vacuo. Cream solid (612mg; 91%).
m/z (API+): 408 (MH+; 100%)
(b) N-(l,2,3,4-Tetrahydroisoquinolin-7-yl)-N' -(3-nitrophenyl) urea
The urea (a) (540mg; 1.32 mmol) in 10% aqueous methanol(80ml) and potassium carbonate (lg) was stirred at room temperature overnight. The mixture was partitioned between chloroform and water and the organic phase dried over magnesium sulfate. Evaporation in vacuo gave a pale yellow solid which was recrystallised from chloroforrmhexane (300mg, 72%). m.p. 232-5 °C.
1H NMR (250MHz, d6-DMSO) δ: 2.48 (2H, t), 2.78 (2H, t), 3.67 (2H, s), 6.83 (IH, d), 7.01 (IH, dd), 7.05 (IH, s), 7.42 (IH, t), 7.53 (IH, d), 7.67 (IH, dd), 8.43 (IH, t), 8.58 (IH, s), 9.07 (lH, s)
Example 2
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-nitrophenyl) urea
The title compound was prepared from amine D5 and 3-nitrophenylisocyanate using a method similar to that of Example 1(a).
lU NMR (250MHz, d6-DMSO) δ: 2.40 (3H, s), 2.58 (2H, t), 2.75 (2H, t), 3.44 (2H, s), 7.01 (IH, dd), 7.02 (IH, d), 7.20 (IH, s), 7.53 (IH, m), 7.68 (IH, m), 7.80 (2H, m), 8.57 (IH, s), 9.19 (IH, s); m/z (API+): 327 (MH+; 100%)
Example 3
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(4-ethoxyphenyl) urea The title compound (262mg) was prepared from amine D5 and 4-ethoxyphenylisocyanate using a method simliar to that of Example 1(a).
m.p. 189-193 °C.
lH NMR (250MHz, d6-DMSO) δ: 1.31 (3H, t), 2.33 (3H, s), 2.56 (2H, t), 2.73 (2H, t), 3.43 (2H, s), 3.97 (2H, q), 7.01 (IH, dd), 6.84 and 7.34 (4H, ABq), 6.98 (IH, d), 7.16 (2H, m), 8.40 (IH, s), 8.44 (IH, s); m/z (API+): 326 (MH+; 100%)
Example 4
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-ethoxyphenyl) urea
The title compound was prepared from amine D9 (162mg; lmmol) in dichloromethane (8ml) and 4-ethoxyphenyl isocyanate (166mg; lmmol) in toluene (4ml) using a method simliar to that of Example 1(a). White powder (210mg).
lH NMR (250MHz, d6-DMSO) δ: 1.42 (3H, t), 2.45 (3H, s), 2.62 (2H, br), 2.76 (2H, br), 3.57 (2H, s), 4.08 (2H, q), 6.83 (IH, d, J=6.5Hz), 6.96 and 7.45 (4H, Abq, J=7.5Hz), 7.19 (IH, t, J=6.5Hz), 7.82 (IH, d, J=6.5Hz), 7.86 (IH, s), 8.95 (IH, s); ra/z(API+): 326 (MH+; 50%)
Example 5
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(3-trifluoromethylphenyl)thiourea
The title compound was prepared in 47% yield from amine D5 and 3-trifluoromethylphenyl isothiocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, d6-DMSO) δ: 2.28 (3H, s), 2.53 (2H, t, J = 6 Hz), 2.74 (2H, t, J = 6
Hz), 3.40 (2H, s), 7.04 (2H, m), 7.13 (IH, dd, J = 2 and 8 Hz), 7.40 (IH, d, J = 8 Hz), 7.50
(IH, t, J = 8 Hz), 7.70 (IH, d, J = 8 Hz), 7.90 (IH, s), 9.87 (2H, b s); m/z (API): 366 (MH+; %)
Example 6
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(3-trifluoromethylphenyl)urea The title compound was prepared in 21% yield from amine D5 and 3-trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.64 (2H, t, J = 6 Hz), 2.84 (2H, t, J = 6
Hz), 3.45 (2H, s), 6.90 - 7.06 (3H, b. m.), 7.09 (IH, s), 7.22 - 7.44 (3H, b. m.), 7.51 (IH, d, J = 8 Hz), 7.58 (IH, s); m/z (APf): 350 (MH+; 100%).
Example 7
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-methoxyphenyl)urea
The title compound was prepared in 74% yield from amine D5 and 3-methoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.35 (3H, s), 2.58 (2H, t, J = 6 Hz), 2.77 (2H, t, J = 6 Hz), 3.32 (2H, s), 3.68 (3H, s), 6.53 (IH, d, J = 8 Hz), 6.76 - 6.96 (3H, b. m.), 7.00 - 7.13 (3H, b. m.), 7.82 (IH, s), 7.93 (IH, s); m/z (APf): 312 (MH+; 100%).
Example 8
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(3-bromophenyl) urea
The title compound was prepared in 90% yield from amine D5 and 3-bromophenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.67 (2H, t, J = 6 Hz), 2.87 (2H, t, J = 6 Hz), 3.50 (2H, s), 6.74 (IH, s), 6.97 (2H, m), 7.02 (2H, d, J = 5 Hz), 7.08 (IH, d, J = 3 Hz), 7.76 (2H, m), 7.53 (IH, s); m/z (API*): 360, 362 (MH+; 100%).
Example 9
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-trifluoromethylphenyl) urea
The title compound was prepared in 90% yield from amine D5 and 4-trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a). Η NMR (250MHz, CDC13) δ: 2.41 (3H, s). 2.63 (2H, t, J = 6 Hz), 2.84 (2H, t, J = 6 Hz),
3.44 (2H, s), 6.93 (2H, m), 7.01 (2H, m), 7.37 (2H, m), 7.45 (3H, m); m/z (APf): 350 (MH+; 100%).
Example 10
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(5-chloro-2,4-dimethoxy-phenyI) urea
The title compound was prepared in 93% yield from amine D5 and 5-chloro-2,4- dimethoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.66 (2H, t, J = 6 Hz), 2.85 (2H, t, J = 6 Hz), 3.48 (2H, s), 3.80 (3H, s), 3.86 (3H, s), 6.45 (IH, s), 7.00 (IH, d, J = 8 Hz), 7.06 - 7.12 (2H, m), 7.32 (IH, s), 7.40 (IH, s), 8.08 (IH, s); m/z (APf): 376 (MH+; 100%).
Example 11
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-tert-butyl, 2- methoxyphenyI)urea
The title compound was prepared in 52% yield from amine D5 and 4-tert-butyl-2- methoxyphenyl isocyanate using a method similar to that of Example 1(a).
lH NMR (250MHz, CDC13) δ: 1.30 (9H, s), 2.44 (3H, s), 2.67 (2H, t, J = 6 Hz), 2.87 (2H, t, J = 6 Hz), 3.52 (2H, s), 3.81 (3H, s), 6.81 (IH, s), 6.87 (IH, d, J = 2 Hz), 6.96 (IH, dd, J = 2 and 8 Hz), 7.07 (3H, m), 7.16 (IH, s), 7.94 (IH, d, J = 8 Hz); m/z (APf): 368 (MH+; 100%)
Example 12
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(phenyl) urea
The title compound was prepared in 94% yield from amine D5 and phenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.41 (3H, s), 2.63 (2H, t, J = 6 Hz), 2.64 (2H, t, J = 6 Hz),
3.45 (2H, s), 6.90 - 7.13 (6H, b. m.), 7.22 - 7.34 (4H, b. m.); m/z (APf): 282 (MH+; 100%). Example 13
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-acetylphenyl)urea
The title compound was prepared in 59% yield from amine D5 and 3-acetylphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.39 (3H, s), 2.55 (3H, s), 2.62 (2H, t, J = 6 Hz), 2.82 (2H, t, J = 6 Hz), 3.42 (2H, s), 6.92 - 7.13 (3H, m), 7.31 (IH, t, J = 8 Hz), 7.44 (IH, d, J = 8 Hz), 7.79 (3H, m), 7.95 (IH, s); m/z (APf): 324 (MH+; 100%).
Example 14
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-methylphenyl)urea
The title compound was prepared in 98% yield from amine D5 and 2-methylphenyl isocyanate using a method similar to that at Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.18 (3H, s), 2.39 (3H, s), 2.61 (2H, t, J = 6 Hz), 2.81 (2H, t, J = 6 Hz), 3.41 (2H, s), 6.88 (IH, s), 6.92 - 7.20 (6H, b. m.), 7.26 (IH, s), 7.54 (IH, d, J = 8 Hz); m/z (APf): 296 (MH+; 100%).
Example 15
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(2-methoxyphenyl)urea
The title compound was prepared in 45% yield from amine D5 and 2-methoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.67 (2H, t, J = 6 Hz), 2.85 (2H, t, J = 6 Hz), 3.48 (2H, s), 3.78 (3H, s), 6.68 - 7.03 (4H, b. m.), 7.09 - 7.22 (2H, b. m.), 7.46 - 7.68 (2H, b. m.), 8.10 (IH, d, J = 7 Hz); "7Z (APf): 312 (MH+; 100%)
Example 16
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-chlorophenyl)urea The title compound was prepared in 92% yield from amine D5 and 3-chlorophenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.47 (3H, s), 2.64 (2H, t, J = 6 Hz), 2.85 (2H, t, J = 6 Hz), 3.46 (2H, s), 6.90 - 7.06 (4H, b. m.), 7.13 - 7.23 (4H, b. m.), 7.37 (IH, s); m/z (APf): 316 (MH+'100%)
Example 17
N-(2-Methyl- l,2,3,4-tetrahydroisoquinolin-7-yl)-N '-(3-chloro-6-methoxypheny l)urea
The title compound was prepared in 98% yield from amine D5 and 3-chloro-6- methoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.66 (2H, t, J = 6 Hz), 2.85 (2H, t, J = 6 Hz), 3.47 (2H, s), 3.77 (3H, s), 6.73 (IH, m), 6.90 (IH, dd, J = 2 and 9 Hz), 7.00 - 7.17 (3H, b. m.), 7.43 (IH, s), 7.60 (IH, s), 8.23 (IH, d, J = 2 Hz); m/z (APf): 346 (100%)
Example 18
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(3,5-di- trifluoromethylphenyI)urea
The title compound was prepared in 41% yield form amine D5 and 3,5- ditrifluoromethylphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 242 (3H, s), 2.66 (2H, t, J = 6 Hz), 2.82 (2H, t, J = 6 Hz), 3.43 (2H, s), 6.89 (IH, s), 6.95 (2H, s), 7.46 (2H, s), 7.81 (2H, s), 8.23 (IH, s); m/z (APf): 418 (100%)
Example 19
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-trifluoromethoxyphenyl)urea
The title compound was prepared in 92% yield from amine D5 and 4- trifluoromethoxyphenyl isocyanate using a method similar to that at Example 1(a). 'H NMR (250MHz. d6-DMSO) δ: 2.49 (3H, s), 2.74 (2H, t, J = 6 Hz), 2.92 (2H, t. J = 6 Hz), 3.61 (2H, s), 7.18 (IH, d, J = 9 Hz), 7.33 (2H, m), 7.45 (2H, d, J = 9 Hz). 7.72 (2H, d. J = 9 Hz), 8.77 (IH, s), 9.03 (IH, s); m/z (APf): 366 (MH+; 100%).
Example 20
N-(2-Methyl-l,2,3,4-tetrahdyroisoquinolin-7-yl)-N'-(3-chloro-4-methyIphenyl)urea
The title compound was prepared in 98% yield from amine D5 and 3-chloro-4- methylphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.28 (3H, s), 2.41 (3H, s), 2.64 (2H, t, J = 6 Hz), 2.84 (2H, t, J = 6 Hz), 3.44 (2H, s), 6.97 (IH, s), 7.01 - 7.16 (4H, b. m.), 7.19 (IH, s), 7.34 (2H, m); m/z (APf): 330 (MH+; 100%).
Example 21
N-(2-Methyl-l,2,3,4,-tetrahydroisoquinolin-5-yl)-N'-(3-trifluoromethyIphenyI)urea
The title compound was prepared from the amine D9 and 3-trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.41 (3H, s), 2.72 (4H, m), 3.54 (2H, s), 6.85 (IH, d, J = 7 Hz), 7.16 (IH, dd, J = 7 and 8 Hz), 7.37 (IH, d, J = 7 Hz), 7.61 (2H, m), 7.74 (IH, d, J = 8 Hz), 8.02 (IH, s), 8.10 (IH, s), 9.44 (IH, s); m/z (APf): 350 (MH+; 100%).
Example 22
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(5-chloro-2,4- dimethoxyphenyl)urea
The title compound was prepared in 54% yield from the amine D9 and 5-chloro-2,4- dimethoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.64 (4H, m), 3.46 (2H, s), 3.84 (3H, s), 3.94 (3H, s), 6.75 (IH, d, J = 7 Hz), 6.85 (IH, s), 7.06 (IH, dd, J = 7 and 8 Hz), 7.67 (IH, d, J = 8 Hz), 8.16 (IH, s), 8.36 (IH, s), 8.62 (IH, s); m/z (APf); 376 (MH+; 100%)
Example 23
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-nitrophenyl)urea The title compound was prepared in 73% yield from amine D9 and 3-nitrophenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz. d6-DMSO) δ: 2.24 (3H, s), 2.57 (4H, m), 3.37 (2H, s), 6.70 (IH, d, J = 7 Hz), 7.02 (IH, t, J = 8 Hz), 7.47 (IH, t, J = 8 Hz), 7.58 (2H, m), 7.73 (IH, m), 7.89 (IH, s), 8.46 (IH, m), 9.43 (IH, s); m/z (APf); 327 (MH+; 100%).
Example 24
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-bromophenyl) urea
The title compound was prepared in 71% yield from amine D9 and 3-bromophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.15 (3H, s), 2.48 (4H, m), 3.27 (2H, s), 6.57 (IH, d, J = 7 Hz), 6.85 - 7.10 (4H, b. m.), 7.46 (IH, d, J = 8 Hz), 7.69 (IH, s), 7.71 (IH, s), 9.03 (IH, s); m/z (APf): 360, 362 (MH+; 100%).
Example 25
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-methoxyphenyl)urea
The title compound was prepared in 47% yield from amine D9 and 3-methoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, d6-DMSO) δ: 2.36 (3H, s), 2.69 (4H, m), 3.52 (2H, s), 3.73 (3H, s), 6.56 (IH, d, J = 10 Hz), 6.76 (IH, d, J = 8 Hz), 6.94 (IH, d, J = 10 Hz), 7.14 (3H, m), 7.72 (IH, d, J = 8 Hz), 7.86 (IH, s), 9.08 (IH, s); m/z (API): 312 (MH+; 100%)
Example 26
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-trifluoromethoxy-phenyl)urea
The title compound was prepared in 74% yield from amine D9 and 4- trifluoromethoxyphenyl isocyanate using a method similar to Example 1(a). Η NMR (250MHz, d6-DMSO) δ: 2.59 (3H, s). 2.84 (2H, t. J = 5 Hz), 3.03 (2H, t, J = 5 Hz), 3.84 (2H, s), 6.82 (IH, d, J = 7 Hz), 7.15 (IH, s), 7.30 (2H, d, J = 8 Hz), 7.58 (2H, d. J = 8 Hz), 7.74 (IH, d, J = 7 Hz), 8.24 (IH, s), 9.59 (IH, s); m/z (APf): 366 (MH+; 100%)
Example 27
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-trifluoromethyl-phenyI)urea
The title compound was prepared in 69% yield from amine D9 and 4-trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.332 (3H, s), 2.58 (2H, t, J = 5 Hz), 2.74 (2H, t, J = 5 Hz), 3.58 (2H, s), 6.60 (IH, d, J = 7 Hz), 6.93 (IH, dd, J = 7 and 8 Hz), 7.45 (5H, m), 8.03 (IH, s), 9.52 (IH, s); m/z (APf): 350 (MH+; 100%)
Example 28
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(phenyl)urea
The title compound was prepared in 79% yield from amine D9 and phenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, d6-DMSO) δ: 2.35 (3H, s), 2.66 (4H, m), 3.48 (2H, s), 6.76 (IH, d, J = 8 Hz), 6.95 (IH, t, J = 8 Hz), 7.08 (IH, t, J = 8 Hz), 7.28 (2H, t, J = 8 Hz), 7.46 (2H, d, J = 8 Hz), 7.71 (IH, d, J = 8 Hz), 7.83 (IH, s), 9.03 (IH, s); m/z (APf): 282 (MH+; 100%).
Example 29
N-(2-Methyl-l,2,3,4-tetrahydroisoqinoIin-5-yl)-N'-(3-acetylphenyl)urea
The title compound was prepared in 74% yield from amine D9 and 3-acetylphenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.43 (3H, S), 2.61 (5H, m), 2.78 (2H, b. m.), 3.56 (2H, s), 6.74 (IH, s), 6.92 (IH, d, J = 7 Hz), 7.16 (IH, t, J = 8 Hz), 7.35 (3H, m), 7.59 (IH, d, J = 8 Hz), 7.80 (2H, m); m/z (APf): 324 (MH+; 100%)
Example 30 N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-5-yl)-N'-(3-chloro-4-methyIphenyl)urea
The title compound was prepared in 98% yield from amine D9 and 3-chloro-4- methylphenyl isocyanate using a method similar that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.29 (3H, s), 2.44 (3H, s), 2.65 (2H, t, J = 6 Hz), 2.76 (2H, t, J = 6 Hz), 3.57 (2H, s), 6.37 (IH, s), 6.71 (IH, s), 6.94 (IH, d, J = 8 Hz), 7.04 - 7.22 (3H, b. m.), 7.33 (2H, m); m/z (APf): 330 (MH+; 100%).
Example 31
N"(2-Methyl-l,2,3,4—tetrahydroisoquinolin-5-yl)-N'-(3-chloro-6-methoxyphenyl)urea
The title compound was prepared in 61% yield from amine D9 and 3-chloro-6- methoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.45 (3H, s), 2.69 (2H, t, J = 6 Hz), 2.82 (2H, t, J = 6 Hz), 3.59 (2H, s), 3.73 (3H, s), 6.41 (IH, s), 6.70 (IH, d, J = 9 Hz), 6.93 (2H, t, J = 6 Hz), 7.18 (IH, t, J = 8 Hz), 7.35 (2H, m), 8.25 (IH, s); m/z (APf): 346 (MH+;100%)
Example 32
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-chlorophenyI)urea
The title compound was prepared in 83% yield form amine D9 and 3-chlorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.60 (2H, t, J = 6 Hz), 2.73 (2H, t, J = 6 Hz), 3.53 (2H, s), 6.70 (IH, s), 6.89(1H, d, J = 8 Hz), 6.98 (IH, m), 7.04 - 7.20 (4H, m), 7.31 (IH, d, J = 8 Hz), 7.37 (IH, s); m/z (APf): 316 (MH+; 100%).
Example 33
N-(2-Methyl-l,2,3,4,-tetrahydroisoquinolin-5-yl)-N'-(2-methoxyphenyl)urea
The title compound was prepared in 58% yield from amine D9 and 2-methoxyphenyl isocyanate using a method similar to that of Example 1(a). Η NMR (250MHz, CDC13) δ: 2.45 (3H, s), 2.68 (2H, t, J = 6 Hz), 2.81 (2H, t, J = 6 Hz). 3.59 (2H. s), 3.75 (3H, s), 6.38 (IH, s), 6.82 (IH, d, J = 7 Hz), 6.88 - 7.04 (3H, b. m.), 7.18 (IH, t, J = 8 Hz), 7.27 (IH, m), 7.40 (IH, d, J = 8 Hz), 8.12 (IH, d, J = 6 Hz); π7z (APf): 312 (MH+; 100%)
Example 34
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2-methylphenyl)urea
The title compound was prepared in 88% yield from amine D9 and 2-methylphenyl isocyanate using a method similar to that of Example 1(a).
'NMR (250MHz, CDC13) δ: 1.71 (3H, s), 2.43 (3H, s), 2.66 (4H, m), 3.55 (2H, s), 6.40 (IH, s), 6.89 (IH, d, J = 8 Hz), 7.05 - 7.28 (5H, m), 7.48 (IH, d, J = 8 Hz), 7.61 (IH, d, J = 8 Hz); m/z (APf): 296 (MH+; 100%)
Example 35
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3,5-di- trifluoromethylphenyl)urea
The title compound was prepared in 58% yield from amine D9 and 3,5-di- trifluoromethylphenyl isocyanate usng a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.46 (3H, s), 2.67 (2H, t, J = 6 Hz), 2.81 (2H, t, J = 6 Hz), 3.59 (2H, s), 6.49 (IH, s), 6.86 (2H, d, J = 8 Hz), 7.16 - 7.34 (2H, b. m.), 7.51(1H, s), 7.83 (2H, s); m/z (APf): 418 (MH+; 100%).
Example 36
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-trifluoromethylphenyl)thiourea
The title compound was prepared in 57% yield from amine D9 and 3-trifluoromethylphenyl isothiocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.46 (3H, s), 2.63 (2H, t, J = 6 Hz), 2.79 (2H, t, J = 6 Hz), 3.54 (2H, s), 7.00 (IH, dd, J = 3 and 6 Hz), 7.14 (2H, m), 7.45 (IH, d, J = 8 Hz), 7.55 (IH, t, J = 8 Hz), 7.79 (IH, d, J = 8 Hz), 8.00 (IH, s), 9.56 (IH, bs), 9.94 ( IH. bs); π7z (APf): 366 (MH+; 95%)
Example 37
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(2-carbomethoxyphenyl) urea
The title compound was prepared in 69% yield from amine D5 and 2-carbomethoxyphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.46 (3H, s), 2.68 (2H, t, J = 6 Hz), 2.89 (2H, t, J = 6 Hz),
3.57 (2H, s), 6.53(1H, br. s.), 7.00 (IH, t), 7.09 (2H, m), 7.19 (IH, s), 7.52 (IH, t), 7.99
(IH, d), 8.54 (IH, d), 10.52 (IH, bs); m/z (APf): 340 (MH+; 95%)
Example 38
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2, 3-dimethylphenyl) urea
The title compound was prepared in 16% yield from amine D5 and 2, 3-dimethylphenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.19 (3H, s), 2.31 (3H, s), 2.43 (3H, s), 2.66 (2H, t, J = 6 Hz), 2.86 (2H, t, J = 6 Hz), 3.53 (2H, s), 6.22 (IH, br. s.), 6.38 (br. s. IH), 7.02 - 7.27 (6H, m); m/z (APf): 310 (MH+; 95%)
Example 39
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-methoxy-3-chlorophenyl) urea
The title compound was prepared in 61% yield from amine D5 and 2-methoxy-3- chlorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.31 (3H, s), 2.56 (2H, t, J = 6 Hz), 2.70 (2H, t, J = 6 Hz), 3.44 (2H, s), 3.77 (3H, s), 6.97 - 7.16 (5H, m), 8.14 (IH, dd), 8.43 (s, IH) and 9.22 (s, IH); m/z (APf): 346 (MH+; 95%)
Example 40 N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(l-naphthyl) urea
The title compound was prepared in 54% yield from amine D5 and l -naphthyl isocyanate using a method similar to that of Example 1 (a).
Η NMR (250MHz, CDC13) δ: 2.42 (3H, s), 2.56 (2H, t, J = 6 Hz), 2.85 (2H, t, J = 6 Hz), 3.51 (2H, s), 6.53 (IH, s), 6.74 (IH, s), 7.01 (2H, d), 7.08 (IH, s), 7.47 - 7.56 (3H, m), 7.67 (IH, d), 7.79 (IH, d), 7.90 (IH, m) and 7.99 (mlH, m).; m/z (APf): 332 (MH+; 95%)
Example 41
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-methyl-3-nitrophenyl) urea
The title compound was prepared in 87% yield from amine D5 and 2-methyl-3-nitrophenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, CDC13) δ: 2.27 (3H, s), 2.44 (3H, s), 2.69 (2H, t, J = 6 Hz), 2.89 (2H, t, J = 6 Hz), 3.53 (2H, s), 6.80 (IH, br. s), 6.86 (IH, br. s), 7.06 (3H, s), 7.30 (IH, t, J = 8 Hz), 7.57 (IH, d, J = 7 Hz) and 7.95 (IH, d, J = 8 Hz); m/z (APf): 339 (MH+; 95%)
Example 42
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-cyanophenyl) urea
The title compound was prepared in 13% yield from amine D5 and 2-cyanophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.47(3H, s) 2.70(2H, br. s.) 3.02(2H, br, s), 3.62(2H, br. s) other aliphatics poorly resolved 6.89(1H, d), 6.97(1H, s), 7.05(1H, d), 7.16(1H, t), 7.32(1H, d), 7.47(1H, s), 8.19(1H, d) and 9.14(1H, br. s.); m/z (APf): 307 (MH+; 95%)
Example 43
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-cyano-3-methylphenyl) urea The isocyanate D10 (160mg) was dissolved in dimethylformamide (10ml), 6-methyl-2- aminobenzonitrile (0.13g) added and the mixture heated at 100°C for 3h. Dimethylformamide was removed at reduced pressure and the residue partitioned between dichloromethane and water. The organic phase was washed with water, dried MgSO4) and solvent removed at reduced pressure. The residue was column chromatographed using a gradient of 0 -> 10 % [9: 1 EtOH - ammonia] in MDC (silica gel ethanol/dichloromethane 1:9 → ammonia/ethanol/dichloromethane 1:9:90) to give the title compound (0.0 lg 3%). Η NMR (250MHz, d6-DMSO) δ: 2.27(3H, s), 2.40 (3H, s), 2.51 (2H, t, J = 6 Hz), 2.69 (2H, t, J = 6 Hz), 3.38 (2H, s), 6.96(1H, d, J = 9 Hz), 7.02(1H, d, J = 8Hz), 7.11(1H, s), 7.14(1H, d), 7.45(1H, t, J = 8 Hz), 7.84(1H, d, 8 Hz), 8.56(1H, s) and 9.25 (IH, s); m/z (APf): 326 (MH+; 95%)
Example 44
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(l-acetyIindolin-7-yl) urea
The title compound was prepared in 14% yield from 7-amino-l-acetylindoline and the isocyanate D10 using the method of Example 43 1H NMR (250MHz, d6-DMSO) δ: 2.41(3H, s), 2.46 (2H, t, J = 5.5 Hz), 2.63(2H, t, J = 5.4 Hz), 2.96(2H, t, J = 7.5 Hz), 3.31(2H, s), 4.03(2H, t, 7.6 Hz), 6.85(2H, m), 7.00QH, t, J = 7.7 Hz), 7.1(2H, m), 7.45(1H, d, J = 8.0 Hz), 8.65(1H, br. s.) and 9.15(1H, br. s.); m/z (APf): 365 (MH+; 95%)
Example 45
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-cyanophenyl) urea
The title compound was prepared in 12% yield from3-aminobenzonitrile and the isocyanate D 10 using the method of Example 43
1H NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.68 (2H, t, J = 5.8Hz), 2.89 (2H, t, J = 5.8Hz), 3.52 (2H, s), 6.88 (IH, br.s), 6.98 - 7.09 (3H, m), 7.19 - 7.39 (3H, m), 7.62 (2H, m). m/z (APf): 307 (MH+)
Example 46
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-ethylphenyl) urea The title compound was prepared in 12% yield from 3-ethylaniline and the isocyanate D10 using the method of Example 43
Η NMR (250MHz. CDC13) δ: 1.19 (3H, t, J = 7.5Hz). 2.42 (3H, s), 2.54 - 2.66 (4H, m), 2.85 (2H, m), 3.48 (2H, s) and 6.90 - 7.26 (7H, m). m/z (APf): 310(MH+)
Example 47
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3, 5-dinitrophenyl) urea
The title compound was prepared in 12% yield from 3,5-dinitroaniline and the isocyanate
D10 using the method of Example 43.
1H NMR (250MHz, d6-DMSO) δ: 2.18 (3H, s), 2.42 (2H, t, J = 5.5Hz), 2.60 (2H, t, J =
5.5Hz), 3.29 (2H, s), 6.88 (IH, d, J = 8.8Hz), 7.06 (2H, br. s), 8.24 (IH, s), 8.59 (2H, d), 8.80 (lH, s) and 9.52 (lH, s). m/z (APf): 372 (MH+)
Example 48
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2,3-dichlorophenyI) urea
The title compound was prepared in 66% yield from amine D5 and 2, 3-dichlorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.46 (3H, s), 2.70 (2H, t, J = 5.8Hz), 2.91 (2H, t, J = 5.8Hz), 3.55 (2H, s), 6.93 (IH, br. s), 7.06 - 7.21 (5H, m), 7.37 (IH, s) and 8.18 (IH, dd, J = 2.1, 7.8Hz). m/z (APf): 350, 352 (MH+)
Example 49
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-chloro-4-fluorophenyl) urea
The title compound was prepared in 95% yield from amine D5 and 3-chloro-4-fluorophenyl isocyanate using a method similar to that of Example 1(a). Η NMR (250MHz, CDC13) δ: 2.40 (3H, s), 2.61 (2H, t, J = 5.2Hz), 2.82 (2H, t, J = 5.2Hz), 3.41 (2H, s), 6.76 - 7.07 (5H, m), 7.26 - 7.35 (2H, m) and 7.42 (IH, s). m/z (APf): 334, 336 (MH+) Example 50
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(2-chloro-5- trifluoromethylphenyl) urea
The title compound was prepared in 24% yield from amine D5 and 2-chloro-5- trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a). Η NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.70 (2H, t, J = 5.2Hz), 2.88 (2H, t, J = 5.2Hz), 3.51 (2H, s), 7.02 - 7.20 (4H, m), 7.38 - 7.49 (2H, m), 8.50 (IH, s) and 8.61 (IH, s). m/z (APf): 384, 386 (MH+)
Example 51
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-isopropoxyphenyI) urea
The title compound was prepared in 42% yield from 3-isopropoxyaniline and the isocyanate D10 using the method of Example 43.
1H NMR (250MHz, CDC13) δ: 1.27 (6H, d, J = 6.0Hz), 2.40 (3H, s), 2.62 (2H, t, J = 5.7Hz), 2.83 (2H, t, J = 5.7Hz), 3.44 (2H, s), 4.48 (IH, m), 6.58 (IH, dd, J = 2.0, 8.2Hz), 6.76 (IH, d, J = 8.0Hz), 6.97 - 7.15 (6H, m) and 7.21 (IH, s). m/z (APf): 340 (MH+)
Example 52
N-(2-Methyl- l,2,3,4-tetrahydroisoquinolin-7-y 1)-N '-(3-ethoxyphenyl) urea
The title compound was prepared in 45% yield from 3-ethoxyaniline and the isocyanate
D10 using the method of Example 43.
Η NMR (250MHz, CDC13) δ: 1.34 (3H, t, J = 6.8Hz), 2.39 (3H, s), 2.62 (2H, t, J = 5.7Hz),
2.81 (2H, m), 3.41 (2H, s), 6.57 (IH, d, 7.7Hz), 6.76 (IH, d, J = 8.0Hz), 6.92 - 6.98 (3H, m) 7.11 (IH, t, J = 8Hz), 7.26 (IH, s) and 7.49 (IH, s). m/z (APf): 326 (MH+)
Example 53
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(3-tertbutylphenyl) urea The title compound was prepared in 39% yield from 3-tertbutylaniline and the isocyanate D10 using the method of Example 43.
Η NMR (250MHz, d6-DMSO) δ: 1.27 (9H, s), 2.32 (3H, s), 2.56 (2H, m), 2.72 (2H, m), 3.43 (2H, s), 7.00 (3H, m), 7.16 - 7.25 (4H, m), 7.45 (IH, s), 8.45 (IH, s) and 8.58 (IH, s). m/z (APf): 338 (MH+)
Example 54
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-[3-(l,3-oxazol-5-yl)phenyl] urea
The title compound was prepared in 72% yield from 3-(l,3-oxazol-5-yl)aniline and the isocyanate D10 using the method of Example 43.
Η NMR (250MHz, d6-DMSO) δ: 2.33 (3H, s), 2.57 (2H, t, J = 5.6Hz), 2.75 (2H, m), 3.45
(2H, s), 7.01 (IH, d, J = 8.3Hz), 7.17 - 7.20 (2H, m), 7.35 (3H, m7.65 (IH, s), 7.'94 (IH, s),
8.48 (IH, s), 8.63 (IH, s) and 8.83 (IH, s). m/z (APf): 349 (MH+)
Example 55
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-benzyloxyphenyl) urea
The title compound was prepared in 78% yield from 3-benzyloxyaniline and the isocyanate D10 using the method of Example 43.
Η NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.55 (2H, t, J = 5.5Hz), 2.73 (2H, m), 3.43 (2H, s), 5.07 (2H, s), 6.62 (IH, d, J = 8.0Hz), 6.92 (IH, d, J = 7.8Hz), 7.00 (IH, d, J = 8.8Hz), 7.17 (3H, m), 7.33 (IH, s), 7.33 - 7.47 (5H, m), 8.58 (IH, s) and 8.68 (IH, s). m/z (APf): 388 (MH+)
Example 56
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-phenoxyphenyl) urea
The title compound was prepared in 75% yield from 3-phenoxyaniline and the isocyanate D10 using the method of Example 43. Η NMR (250MHz. d6-DMSO) δ: 2.31 (3H, s), 2.55 (2H, t, J = 5.5Hz), 2.73 (2H, m), 3.42 (2H, s), 6.60 (IH. d. J = 7.1Hz), 6.95 - 7.29 (9H, m), 7.40 (2H, m), 8.48 (IH, s) and 8.74 (lH, s). m/z (APf): 374 (MH+)
Example 57
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-fluorophenyI) urea
The title compound was prepared in 37% yield from amine D5 and 3 -fluorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.33 (3H, s), 2.58 (2H, m), 2.72 (2H, m), 3.45 (2H, s),
6.76 (IH, t, J = 6.7Hz), 6.99 - 7.33 (5H, m), 7.48 (IH, d, J = 12Hz), 8.58 (IH, s) and 8.85 (IH, s). m/z (APf): 300 (MJf)
Example 57
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(2-fluorophenyl) urea
The title compound was prepared in 45% yield from amine D5 and 2-fluorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.56 (2H, t, J = 5.6Hz), 2.74 (2H, m), 3.44 (2H, s), 6.95 - 7.31 (6H, m), 8.15 (IH, t), 8.50 (IH, s) and 8.96 (IH, s). m/z (APf): 300 (MH+)
Example 58
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-methylthiophenyl) urea
The title compound was prepared in 58% yield from amine D5 and 3-methylthiophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.33 (3H, s), 2.45 (3H, s), 2.56 (2H, t, J = 5.6Hz), 2.74 (2H, m), 3.44 (2H, s), 6.85 (IH, d, J = 7.5Hz), 6.99 (IH, d, J = 8.8Hz), 7.10 - 7.24 (4H, m), 7.47 (IH, s), 8.53 (IH, s) and 8.65 (IH, s). m/z (APf): 328 (MH+) Example 59
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-carboethoxyphenyl) urea
The title compound was prepared in 91% yield from amine D5 and 3-carboethoxyphenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 1.33 (3H, t, J = 7.0Hz), 2.37 (3H, s), 2.60 (2H, m), 2.78 (2H, m), 3.37 (2H, s), 4.30 (2H, q, J = 7.0Hz), 6.91 - 7.05 (3H, m), 7.26 (IH, t, J = 7.8Hz), 7.66 (3H, m) and 7.82 - 7.90 (2H, m). m/z (APf): 354 (MH+)
Example 60
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-fluorophenyl) urea
The title compound was prepared in 98% yield from amine D5 and 4-fluorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.55 (2H, m), 2.74 (2H, m), 3.43 (2H, s),
6.97 - 7.15 (5H, m), 7.45 (2H, m), 7.52 (IH, s) and 7.67 (IH, s). m/z (APf): 300 (MH+)
Example 61
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3, 4-difluorophenyl) urea
The title compound was prepared in 72% yield from amine D5 and 3, 4-difluorophenyl isocyanate using a method similar to that of Example 1(a).
Η NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.56 (2H, t, J = 5.5Hz), 2.74 (2H, m), 3.43
(2H, s), 7.0 (IH, d, J = 8.7Hz), 7.08 - 7.15 (2H, m), 7.27 - 7.37 (2H, m), 7.61 - 7.73 (IH, m), 8.60 (lH, s) and 8.84 (lH, s). m/z (APf): 318 (MH+)
Example 62
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(3-benzoylphenyl) urea
The title compound was prepared in 67% yield from 3-benzoylaniline and the isocyanate D10 using the method of Example 43. Η NMR (250MHz. d6-DMSO) δ: 2.32 (3H, s), 2.56 (2H, m). 2.73 (2H, m). 3.42 (2H, s). 6.99 (IH, d), 7.16 (2H, m), 7.32 (IH, d), 7.39 - 7.80 (7H, m), 7.87 (IH, s), 8.55 (IH, s) and 8.92 (lH, s). m/z (APf): 386 (MH+)
Example 63
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yI)-N'-(4-methoxyphenyl) urea
The title compound was prepared in 96% yield from 4-methoxyaniline and the isocyanate
D10 using the method of Example 43.
Η NMR (250MHz, d6-DMSO) δ: 2.32 (3H, s), 2.56 (2H, m), 2.73 (2H, m), 3.43 (2H, s),
3.71 (3H, s), 6.85 (2H, d, J = 8.7Hz), 6.98 (IH, d, J = 9.0Hz), 7.14 (2H, m), 7.33 (2H, d, J
= 8.7Hz), 8.45 (IH, s) and 8.48 (IH, s). m/z (APf): 312 (MH+)
Example 64
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-bromo-4-methoxyphenyl) urea
A solution of 3-bromo-4-methoxybenzoic acid (0.924g) in dioxan (10ml) was treated with l,8-bis(dimethylamino)naphthalene (0.857g). After stirring for 30min diphenylphosporyl azide was added and the mixture boiled for 6h. After cooling to room temperature the amine D5 (0.245g) in dichloromethane (10ml) was added and the mixture stirred for 16h. Solvent was removed at reduced pressure, the residue column chromatographed (methanol/dichloromethane mixtures) to give the title compound (0.34g). Η NMR (250MHz, d6-DMSO) δ: 2.82 (3H, s), 2.96 (2H, m), 3.38 (4H, m), 3.79 (3H, s), 4.20 (2H, s), 6.95 - 7.35 (5H, m), 7.79 (IH, m), 9.10 (IH, s), 9.13 (IH, s) and 10.30 (IH, br. s). m/z (APf): 390, 392 (MH+)
Example 65
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-bromo-4-methoxyphenyl) urea
The title compound was prepared in 24% yield from amine D9 and 3-bromo-4- methoxybenzoic acid using the method of Example 64. NMR (250MHz, CDC13) δ: 2.38 (3H, s). 2.76 (2H, m), 2.83 (2H, m), 3.66 (2H, s), 3.81 (3H, s), 6.60 (IH, d, J = 7.5Hz), 6.67 (IH, d, J = 8.9Hz), 7.17 (IH, m), 7.60 (IH, d, J = 2.4Hz), 7.69 (IH, d), 8.02 (IH, s), 8.70 (IH, s). m/z (APf): 390, 392 (MH+)
Example 66
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2,3-dichlorophenyl) urea
The title compound was prepared in 95% yield from amine D9 and 2,3-dichloropphenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.47 (3H, s), 2.71 (2H, m), 2.85 (2H, m), 3.62 (2H, s), 6.51 (IH, br. s), 7.00 (IH, d, J = 7.7Hz), 7.09 - 7.35 (5H, m) and 8.17 (IH, d, J = 7.7Hz). m/z (APf): 350, 352 (MH+)
Example 67
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2-chloro-5- trifluoromethylphenyl) urea
The title compound was prepared in 36% yield from amine D9 and 2-chloro-5- trifluoromethylphenyl isocyanate using a method similar to that of Example 1(a). Η NMR (250MHz, CDC13) δ: 2.45 (3H, s), 2.67 (2H, m), 2.83 (2H, m), 3.58 (2H, s), 6.91 (IH, br. s), 6.98 (IH, d, J = 7.5Hz), 7.17 - 7.46 (5H, m) and 8.60 (IH, s). "7Z (APf): 384, 386 (MH+)
Example 68
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yI)-N'-(3-chloro-4-fluorophenyl) urea
The title compound was prepared in 90% yield from amine D9 and 3-chloro-4-fluorophenyl isocyanate using a method similar to that of Example 1(a).
1H NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.64 (2H, m), 2.75 (2H, m), 3.56 (2H, s), 6.44
(IH, br. s), 6.82 (IH, br. s), 6.94 - 7.29 (5H, m) and 7.44 (IH, m). m/z (APf): 334, 336 (MH+)
Example 69 N-(2-MethyI-l,2,3,4-tetrahydroisoquinoIin-5-yl)-N'-(4-methoxyphenyI) urea
A mixture of the amine D9 (0.245g) and carbonyl diimidazole (0.245g) in dichloromethane (10ml) was stirred for 45 min at room temperature. Solvent was removed at reduced pressure and a solution of 4-methoxyaniline (0.185g) in dimethylformamide (10ml) added. The mixture was heated at 100°C for 1 h. solvent removed at reduced pressure and the residue column chromato graphed (silica gel, ether/methanol and dichloromethane/methanol mixtures) to give the title compound (0.25g).
Η NMR (250MHz, d6-DMSO) 2.33 (3H, s), 2.65 (4H, m), 3.46 (2H, s), 3.71 (3H, s), 6.72 (IH, d, J = 7.5Hz), 6.86 (2H, d, J = 8.9Hz), 7.06 (IH, t, J = 7.8Hz), 7.35 (2H, d, J = 8.9Hz), 7.70 (IH, d, J = 8.0Hz), 7.77 (IH, s) and 8.88 (IH, s). m/z (APf): 311 (MH+)
Example 70
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-ethylphenyl) urea
The title compound was prepared in 55% yield from amine D9 and 3-ethylaniline using a method similar to that of Example 69. 1H NMR (250MHz, CDC13) δ: 1.19 (3H, t, J = 7.6Hz), 2.43 (3H, s), 2.55 - 2.96 (6H, m), 3.56 (2H, s), 6.43 (IH, s), 6.77 (IH, s), 6.91 (2H, d, J = 7.5Hz), 7.11 - 7.23 (4H, m) and 7.40 (IH, d, J = 7.8Hz). m/z (APf): 310 (MH+)
Example 71
N-(2-MethyI-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3, 5-dinitrophenyl) urea
The title compound was prepared in 24% yield from amine D9 and 3, 5-dinitroaniline using a method similar to that of Example 69.
1H NMR (250MHz, d6-DMSO) δ: 2.35 (3H, s), 2.64 - 2.76 (4H, m), 3.63 (2H, s), 6.85 (IH, d, J = 7.5Hz), 7.13 (IH, t, J = 7.7Hz), 7.56 (IH, d, J = 8.0Hz), 8.21 (IH, s), 8.39 (IH, t),
8.73 (2H, d) and 10.04 (lH, s). m/z (APf): 372 (MH+)
Example 72
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-cyanophenyl) urea The title compound was prepared in 56% yield from amine D9 and 3-aminobenzonitrile using a method similar to that of Example 69.
Η NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.64 (2H, m), 2.74 (2H, m), 3.57 (2H, s), 6.23 (IH, s), 6.82 (IH, d, J = 7.3Hz), 7.14 - 7.36 (5H, m), 7.55 (IH, d. J = 8.0Hz). 7.64 (IH, s). m/z (APf): 307 (MH+)
Example 73
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-5-yI)-N'-(3-bromo-4-methoxyphenyl) urea
The title compound was prepared in 20% yield from amine D9 and 3-bromo-4- methoxyaniline using a method similar to that of Example 69.
1H NMR (250MHz, CDC13) δ: 2.46 (3H, s), 2.72 - 2.77 (4H, m), 3.57 (2H, s), 3.89 (3H, s), 6.61 (IH, dd, J = 2.5, 8.5Hz), 7.13 (IH, t, J = 7.7Hz), 7.35 (IH, d, J = 8.4Hz), 7.54 (IH, s), 7.65 (IH, d, J = 2.5Hz), 7.70 (IH, d, J = 8.0Hz) and 8.67 91H, s). m/z (APf ): 389, 391 (MH+)
Example 74
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-7-yl)-N'-(3-aminophenyl) urea
N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-nitrophenyl) urea E2 (1.2g) was dissolved in ethanol (50ml), purged with argon and treated with 10% palladium/charcoal (O.lg, paste) and ammonium formate (l.lόg). The mixture was stirred at room temperature for 16h, filtered (celite pad) and the filtrate evaporated under reduced pressure. The obtained residue was dissolved in water, basified with sodium carbonate and the precipitated title compound (0.98g) collected by filtration. Η NMR (250MHz, d6-DMSO) δ: 2.71 (3H, s), 2.76 (2H, m), 2.93 (2H, m), 3.63 (2H, s), 5.22 (2H, br. s), 6.08 91H, d, J = 7.8Hz), 6.45 (IH, d, J = 7.9Hz), 6.67 (IH, s), 6..78 (IH, t, J = 8.0Hz), 6.88 (IH, m), 7.06(2H, m), 8.26 (IH, s) and 8.36 (IH, s). m/z (APf): 297 (MH+)
Example 75
N-{3-[3-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl}acetamide hydrochloride A solution of N-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-aminophenyl) urea E74 (0.296g) and triethylamine (0.151g) in dichloromethane was treated with acetyl chloride (0.078g) and stirred for 6h. Aqueous sodium hydrogen carbonate was added with vigorous stirring and the precipitated solid collected by filtration. The material was dissolved in methanol and treated with an excess of ethereal HC1. The precipitated title compond (0.145g) was collected by filtration and dried in vacuo.
Η NMR (400MHz, d6-DMSO) δ: 2.03 (3H, s), 2.86 (3H, s), 2.94 (IH, m). 3.17 (IH, m), lresonance under HOD, 3.58 (IH, m), 4.21 (IH, m), 4.40 (IH, m), 7.12 - 7.15 (3H, m), 7.26 - 7.32 (2H, m), 7.35 91H, s), 7.68 91H, s), 9.44 91H, s), 9.62 (IH, s) and 10.00 (IH, s). m/z (APf): 339 (MH+)
Example 76
N-{3-[3-(2-Methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl}bis methanesulphonimide hydrochloride
A solution of N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-aminophenyl) urea E74 (0.150g) and triethylamine (0.21ul) in dichloroethane was treated with methanesulphonyl chloride (0.085ul) and stirred for 16h. The organic phase was washed with water, aqueous sodium hydrogen carbonate and brine. Solvent was removed at reduced pressure and the residue converted to the HC1 salt (see Example 75) of the title compound (0.082g). Η NMR (250MHz, CDC13) δ: 2.44 (3H, s), 2.690 (2H, m), 2.85 (2H, m), 3.40 (6H, s), 3.50
(2H, s), 6.97 - 7.02 (4H, m), 7.19 (IH, s), 7.20 - 7.29 (2H, m), 7.49 (IH, s) and 7.68 (IH, m). m/z (APf): 453 (MH+)
Example 77
N-(2-Methyl-l,2,3,4-tetrahydroisoquinoIin-5-yl)-N'-(l-methylindol-5-yl) urea
The title compound was prepared in 68% yield from amine D9 and l-methyl-5- aminoindole using a method similar to that of Example 69.
Η NMR (250MHz, CDC13) δ: 2.33 (3H, s), 2.65 (4H, m), 3.45 (2H, s), 3.75 (3H, s), 6.34 (IH, d, J = 2.8Hz), 6.72 (IH, d, J = 7.5Hz), 6.03 - 7.16 (2H, m), 7.26 (IH, d, J = 3.0Hz), 7.33 (IH, d, J = 8.7Hz), 7.51 - 7.58 (3H, m) and 8.63 (IH, s). m/z (APf): 335 (MH+)
PHARMACOGICAL DATA
1. Binding Assay Method
WO 92/22293 (SmithKline Beecham) discloses compounds having anti-convulsant activity, including ter alia the compound trαnO+)-6-acetyl-4S-(4-fluorobenzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-l-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham). The affinity of test compounds to the novel receptor site is assessed as follows.
Method
Whole forebrain tissue is obtained from rats. The tissue is first homogenised in buffer (usually 50mM Tris/HCl, pH 7.4). The homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.
To carry out the radioligand binding assay, aliquots of tissue prepared as above (usually at a concentration of l-2mg protein/ml) are mixed with aliquots of [3H] -Compound A dissolved in buffer. The final concentration of [3H]-Compound A in the mixture is usually 20nM. The mixture is incubated at room temperature for 1 hour. [3H]-Compound A bound to the tissue is then separated from unbound [3H]-Compound A by filtration through Whatman GF/B glass fibre filters. The filters are then washed rapidly with ice-cold buffer. The amount of radioactivity bound to the tissue trapped on the filters is measured by addition of liquid scintillation cocktail to the filters followed by counting in a liquid scintillation counter.
In order to determine the amount of "specific" binding of [3H]-Compound A, parallel assays are carried out as above in which [3H] -Compound A and tissue are incubated together in the presence of unlabelled Compound A (usually 3 μM). The amount of binding of [3H]-Compound A remaining in the presence of this unlabelled compound is defined as "non-specific" binding. This amount is subtracted from the total amount of [3H]- Compound A binding (i.e. that present in the absence of unlabelled compound) to obtain the amount of "specific" binding of [3H] -Compound A to the novel site. The affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested. The decrease in the level of specific [3H]- Compound A binding as a result of competition by increasing concentrations of the compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.
Results
Compounds of this invention were active in this test with pKi values greater than 6. For example, compounds of Examples 1, 2, 6, 7, 8, 16 and 23 gave pKi values greater than 8.
2. MEST Test
The maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties 1. In this model, anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.
Method
Mice (naive male, Charles River, U.K. CD-I strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC50) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)2. Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)3.
In control animals the CC50 is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.
The percentage increase or decrease in CC50 for each group compared to the control is calculated. Studies are carried out using a Hugo Sachs Electronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.
Drugs are suspended in 1 % methyl cellulose.
References
1. Loscher, W. and Schmidt, D. (1988). Epilepsy Res., 2, 145-181 2. Dixon, W.J. and Mood, A.M. (1948). J. Amer. Stat. Assn., 43, 109-126
3. Litchfield, J.T. and Wilcoxon, F.(1949). J. Pharmacol, exp. Ther., 96, 99-113
Results
Compounds of this invention dosed by the oral route as a suspension in methyl cellulose and tested one hour post dosing show an increase in seizure threshold. For example, the product of Example 1 showed a statistically significant increase (35%) when examined at a dose of 10 mg/kg p.o.

Claims

1, A compound of formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000047_0001
where X is O or S R is hydrogen, phenylCj.g alkyl or C g alkyl,
2 . R is hydrogen or up to three substituents independently selected from halogen,
NO2, CN, N3, C . alkylO-, C1-6 alkylS-, C g alkyl, C^haloalkyl,
C3_gcycloalkyl, C3_6cycloalkyl-C 4alkyl-, C^alkenyl, C^.galkynyl,
C╬╣.6haloalkylCO-, C╬╝galkyICO-, C3.6cycloalkylCO-, C3_6cycloalkyl-C^_4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C^alkyl-, O-C╬╣_6haloalkyl, CO2Ci_4alkyl, S(O)2C╬╣_6alkyl,
Figure imgf000047_0002
or heterocyclyl, or -NR"R where
R┬░ is hydrogen, \_^ alkyl or S(O)2Cj.6alkyl, and
R7 is hydrogen, C╬╣.4alkyl, -CHO, S(O)2C╬╣_6alkyl -CO2C1.4alkyl or -COC^alkyl, or an adjacent pair of R2 groups together with the carbon atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring.
2. A compound of claim 1 which is a (tetrahydroisoquinolin-5-yl) or (tetrahydroisoquinolin-7-yl) urea or thiourea.
3. A compound of claim 1 in which
R is hydrogen, benzyl, methyl, ethyl, t^o-propyl or t-butyl
R2 is hydrogen, methyl, ethyl, n-butyl, z'sσ-propyl, t-butyl, phenyl, benzyl, methoxy, ethoxy, n-propoxy, wo-propoxy, π-butoxy, phenoxy, benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl, pivaloyl, /sσ-butyroyl, benzoyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, carbomethoxy, carboethoxy, methylthio, n-propylsulfonyl, isopropylsulfonyl, dimethylsulfamoyl or oxazolyl, R° and R^are independently hydrogen, acetyl or methanesulfonyl, or two R2 groups linked to form naphthyl, indolyl or idolinyl, optionally substituted by acetyl or methyl.
4. A compound of claim 1 in which R s hydrogen or methyl,
R2 is hydrogen, methyl, ethyl, t-butyl, methoxy, ethoxy, wo-propoxy, phenoxy, benzyloxy, methylthio, bromo, chloro, fluoro, nitro, cyano, acetyl, benzoyl, trifluoromethyl, trifluoromethoxy, carbomethoxy, carboethoxy, amino, acetylamino, methanesulphonylamino or oxazolyl, or two R2 groups form methylindolyl or acetylindolinyl or naphthyl.
5. A A ccoomm]pound of claim 1 which is
N-( 1,2,3, 4-tet rrahydroisoquinolin-7-yl)-N'-(3-nitrophenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-nitrophenyl) urea
N-(2-methyl-l ,2,3 ,4-tetrahydroisoquinolin-7-yl)-N (4-ethoxyphenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N (4-ethoxyphenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-trifluoromethylphenyl)thiourea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-trifluoromethylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-methoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-bromophenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinplin-7-yl)-N (4-trifluoromethylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (5-chloro-2,4-dimethoxyphenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (4-tert-butyl, 2-methoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (phenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-acetylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (2-methylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (2-methoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-chlorophenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3-chloro-6-methoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (3,5-di-trifluoromethylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N (4-trifluoromethoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahdyroisoquinolin-7-yl)-N - (3-chloro-4-methylphenyl)urea
N-(2-methyl-l ,2,3,4,-tetrahydroisoquinolin-5-yl)-N'- (3-trifluoromethylphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N'- (5-chloro-2,4-dimethoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N'- (3-nitrophenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N - (3-bromophenyl) urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N' (3-methoxyphenyl)urea
N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N - (4-trifluoromethyoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl N '-(4-trifluoromethylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl N'-(phenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoqinolin-5-yl)- N'-(3-acetylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl -N'-(3-chloro-4-methylphenyl)urea N-(2-methyl- ,2,3,4ΓÇö tetrahydroisoquinolin-5- )-N -(3-chloro-6-methoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl -N'-(3-chlorophenyl)urea N-(2-methyl- ,2,3,4,-tetrahydroisoquinolin-5-y )-N'-(2-methoxyphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl -N '- (2-methylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl -N'-(3,5-di-trifluoromethylphenyl)urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-5-yl N'-(3-trifluoromethylphenyl)thiourea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N '-(2-carbomethoxyphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(2, 3-dimethylphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(2-methoxy-3-chlorophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(l -naphthyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(2-methyl-3-nitrophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(2-cyanophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(2-cyano-3-methylphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(l-acetylindolin-7-yl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(3-cyanophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl -N'-(3-ethylphenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl N'-(3, 5-dinitrophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl N'-(2, 3-dichlorophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl N'-(3-chloro-4-fluorophenyl) urea N-(2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl N'-(2-chloro-5-trifluoromethylphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-isopropoxyphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-ethoxyphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-tertbutylphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- [3-(l,3-oxazol-5-yl)phenyl] urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-benzyloxyphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-phenoxyphenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-fluorophenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (2-fluorophenyl) urea
N- (2-methyl ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-methylthiophenyl) urea
N- (2-methyl- ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-carboethoxyphenyl) urea
N- (2-methyl ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (4-fluorophenyl) urea
N- (2-methyl ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3, 4-difluorophenyl) urea
N- (2-methyl ,2,3,4-tetrahydroisoquinolin-7-yl)-N'- (3-benzoylphenyl) urea N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-bromo-4-methoxyphenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N '-(3-bromo-4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2,3-dichlorophenyl) urea N-(2-methyl-l ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(2-chloro-5-trifluoromethylphenyl) urea
N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-chloro-4-fluorophenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(4-methoxyphenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-ethylphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3, 5-dinitrophenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-cyanophenyl) urea N-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(3-bromo-4-methoxyphenyl) urea N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-7-yl)-N'-(3-aminophenyl) urea N- { 3-[3-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl } acetamide N-{ 3-[3-(2-methyl- 1 ,2,3,4-tetrahydroisoquinolin-7-yl)ureido]phenyl }bis methanesulphonimide or N-(2-methyl-l,2,3,4-tetrahydroisoquinolin-5-yl)-N'-(l-methylindol-5-yl) urea.
6. A process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (LI)
0D
where R1A is R as defined for formula (I) or a group convertible to R* , and P is NH2 or NCX, X being as defined for formula (I),
with a compound of formula (ILL)
(ΠD
where Q is NCX or NH2 and different from P, X being as defined for formula (I), and R2A is R^ as defined for formula (I) or a group or groups convertible to R2, and where required converting a R^ or R ^ group to a R* or R2 group, converting one R ! or R2 group to another R or R2 group, converting a salt product to the free base or another pharmaceutically acceptable salt, or converting a free base product to a pharmaceutically acceptable salt.
7. A pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post- traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and/or amyotrophic lateral sclerosis (ALS) which comprises a compound of formula (L), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
8. A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with ALDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and/or amyotrophic lateral sclerosis (ALS) comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
9. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression, panic disorders and/or aggression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post- traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with ALDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Giles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and/or amyotrophic lateral sclerosis (ALS).
10. A compound of formula (I) or pharmaceutically acceptable salt thereof:
Figure imgf000052_0001
where X is O or S,
R is hydrogen or C^_ alkyl,
2 R is hydrogen or up to three substituents independently selected from halogen,
CF3, NO2, CN, N3, C ι _6 alkylO-, Cχ_6 alkylS-, Cγ.β alkyl, C3_gcycloalkyl, C3_ cycloalkyl-C 4alkyl-, C galkenyl, Cj.galkynyl,
CF3CO-, CF3O, C galkylCO-, C3.6cycloalkylCO-,
C3_ cycloalkyl-C╬╣_4alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C^alkyl-, heterocyclyl, or -NR┬░R where
R is hydrogen or C 1.4 alkyl, and R7 is hydrogen, C╬╣ _ alkyl, -CHO, -CO2C1.4alkyl or -COC^alkyl.
PCT/GB1998/002728 1997-09-12 1998-09-09 Substituted isoquinolines as anticonvulsivants WO1999014197A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002303777A CA2303777A1 (en) 1997-09-12 1998-09-09 Substituted isoquinolines as anticonvulsivants
EP98942869A EP1005459A1 (en) 1997-09-12 1998-09-09 Substituted isoquinolines as anticonvulsivants
JP2000511748A JP2001516745A (en) 1997-09-12 1998-09-09 Substituted isoquinolines as anticonvulsants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9719530.9A GB9719530D0 (en) 1997-09-12 1997-09-12 Novel compounds
GB9719530.9 1997-09-12

Publications (1)

Publication Number Publication Date
WO1999014197A1 true WO1999014197A1 (en) 1999-03-25

Family

ID=10819042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1998/002728 WO1999014197A1 (en) 1997-09-12 1998-09-09 Substituted isoquinolines as anticonvulsivants

Country Status (5)

Country Link
EP (1) EP1005459A1 (en)
JP (1) JP2001516745A (en)
CA (1) CA2303777A1 (en)
GB (1) GB9719530D0 (en)
WO (1) WO1999014197A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008022A1 (en) * 1998-08-05 2000-02-17 Smithkline Beecham Plc Urea derivatives
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1472215A2 (en) * 2002-02-08 2004-11-03 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110137941A (en) * 2010-06-18 2011-12-26 (주) 에빅스젠 Novel thiourea or urea derivative, process for preparing the same and pharmaceutical composition for preventing or treating aids comprising the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018028A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
WO1996024588A1 (en) * 1995-02-11 1996-08-15 Astra Aktiebolag Bicyclic isothiourea derivatives useful in therapy
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018028A1 (en) * 1992-03-12 1993-09-16 Smithkline Beecham Plc Indole derivatives as 5ht1c antagonists
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
WO1996024588A1 (en) * 1995-02-11 1996-08-15 Astra Aktiebolag Bicyclic isothiourea derivatives useful in therapy
WO1996039382A1 (en) * 1995-06-06 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives as 5-ht antagonists

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000008022A1 (en) * 1998-08-05 2000-02-17 Smithkline Beecham Plc Urea derivatives
EP1472215A2 (en) * 2002-02-08 2004-11-03 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors
EP1472215A4 (en) * 2002-02-08 2007-05-09 Bristol Myers Squibb Co (oxime)carbamoyl fatty acid amide hydrolase inhibitors
WO2004085433A2 (en) * 2003-03-28 2004-10-07 Pharmacia & Upjohn Company Llc Positive allosteric modulators of the nicotinic acetylcholine receptor
WO2004085433A3 (en) * 2003-03-28 2004-12-16 Upjohn Co Positive allosteric modulators of the nicotinic acetylcholine receptor

Also Published As

Publication number Publication date
GB9719530D0 (en) 1997-11-19
CA2303777A1 (en) 1999-03-25
JP2001516745A (en) 2001-10-02
EP1005459A1 (en) 2000-06-07

Similar Documents

Publication Publication Date Title
JP2001507349A (en) Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
AU737955B2 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
WO2000007993A1 (en) Substituted isoquinoleines and their use as anticonvulsivants
US20010016657A1 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
CA2575785A1 (en) 5-ht7 receptor antagonists
US6110934A (en) Substituted benzamide derivatives and their use as anticonvulsants
WO2006018308A1 (en) 5-ht7 receptor antagonists
US6274594B1 (en) Isoquinoline derivatives and their therapeutical use
US6248754B1 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
EP0861250B1 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
EP1005459A1 (en) Substituted isoquinolines as anticonvulsivants
CA2303994A1 (en) N-5,6,7,8-tetrahydro(1,6)naphthyridine-n'-phenylurea derivatives
US6277861B1 (en) Anti-convulsant isoquinolyl-benzamide derivatives
EP1200409B1 (en) Substituted isoquinoline derivatives and their use as anticonvulsants
WO2000008022A1 (en) Urea derivatives
JPH02262576A (en) New compound, prearation thereof, and pharmaceutical composition containing same
KR20000016715A (en) Substituted benzamide derivatives and their use as anticonvulsants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998942869

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2303777

Country of ref document: CA

Ref country code: CA

Ref document number: 2303777

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09508485

Country of ref document: US

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1998942869

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998942869

Country of ref document: EP